TrialJournal of cancer research and clinical oncology2013

Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.

Andreas Hochhaus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.